Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: A 1-year study

Nephrology Dialysis Transplantation

Volumn 24, Issue 9, 2009, Pages 2899-2908

  Kim, Sejoong ^a   Oh, Jieun ^b   Kim, Suhnggwon ^c   Chung, Wookyung ^a   Ahn, Curie ^c   Kim, Sung Gyun ^b   Oh, Kook Hwan ^c  

^a Gachon University College of Medicine   (South Korea)

^b Hallym University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

End stage renal disease; Glucose degradation products; Peritoneal dialysis; Randomized controlled trials; Residual renal function

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CA 125 ANTIGEN; CARBON DIOXIDE; INTERLEUKIN 6;

ADULT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; INFLAMMATION; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MESOTHELIUM CELL; PERITONEAL DIALYSIS; PERITONITIS; PRESERVATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ADULT; AGED; BIOCOMPATIBLE MATERIALS; CA-125 ANTIGEN; DIALYSIS SOLUTIONS; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSE; HUMANS; HYDROGEN-ION CONCENTRATION; INTERLEUKIN-6; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MATERIALS TESTING; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 69249088031     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp054     Document Type: Article

References (40)

1. Bargman JM, Thorpe KE, Churchill DN. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158-2162
2. Paniagua R, Amato D, Vonesh E et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13: 1307-1320
3. Termorshuizen F, Korevaar JC, Dekker FW et al. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 2003; 41: 1293-1302
4. Lee HY, Park HC, Seo BJ et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25: 248- 255
5. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418
6. Millar DJ, Holmes C, Faict D et al. Comparison of in vitro AGE formation between standard PD fluid and a novel bicarbonate/lactate formulation. Adv Perit Dial 1998; 14: 191-194
7. Witowski J, Korybalska K, Wisniewska J et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000; 11: 729-739
8. Justo P, Sanz AB, Egido J et al. 3,4-Dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005; 54: 2424- 2429
9. Fan SL, Pile T, Punzalan S et al. Randomized controlled study of biocompatible peritoneal dialysis solutions: effect on residual renal function. Kidney Int 2008; 73: 200-206
10. Szeto CC, Chow KM, Lam CW et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products-a 1-year randomized control trial. Nephrol Dial Transplant2007; 22: 552-559
11. Davies SJ, Russell L, Bryan J et al. Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: their interrelationship and prediction of survival. Am J Kidney Dis 1995; 26: 353-361
12. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Nutrition 1989; 5: 303- 311; discussion 312-303
13. Watson PE, Watson ID, Batt RD. Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr 1980; 33: 27-39
14. Smit W, van Dijk P, Langedijk MJ et al. Peritoneal function and assessment of reference values using a 3.86% glucose solution. Perit Dial Int 2003; 23: 440-449
15. Piraino B, Bailie GR, Bernardini J et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25: 107-131
16. Schrier R, McFann K, Johnson A et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomaldominant polycystic kidney disease: results of a seven-year prospective randomized study. J Am Soc Nephrol 2002; 13: 1733-1739
17. Hiroshige K, Yuu K, Soejima M et al. Rapid decline of residual renal function in patients on automated peritoneal dialysis. Perit Dial Int1996; 16: 307-315
18. Hufnagel G, Michel C, QueffeulouGet al. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant 1999; 14: 1224-1228
19. Singhal MK, Bhaskaran S, Vidgen E et al. Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int 2000; 20: 429-438
20. Rippe B, Simonsen O, Heimburger O et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59: 348-357
21. Schmitt CP, von Heyl D, Rieger S et al. Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content. Nephrol Dial Transplant2007; 22: 2038-2044
22. Zeier M, Schwenger V, Deppisch R et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63: 298-305
23. Vlassara H, Striker LJ, Teichberg S et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 1994; 91: 11704-11708
24. Wang X, Desai K, Clausen JT et al. Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kidney Int 2004; 66: 2315-2321
25. Konings CJ, Kooman JP, Gladziwa U et al. A decline in residual glomerular filtration during the use of icodextrin may be due to underhydration. Kidney Int 2005; 67: 1190-1191
26. Konings CJ, Kooman JP, Schonck M et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 2003; 63: 1556-1563
27. Combet S, Miyata T, Moulin P et al. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol2000; 11: 717-728
28. Steinhauer HB, Schollmeyer P. Prostaglandin-mediated loss of proteins during peritonitis in continuous ambulatory peritoneal dialysis. Kidney Int 1986; 29: 584-590
29. Fang W, Mullan R, Shah H et al. Comparison between bicarbonate/ lactate and standard lactate dialysis solution in peritoneal transport and ultrafiltration: a prospective, crossover single-dwell study. Perit Dial Int 2008; 28: 35-43
30. Montenegro J, Saracho RM, Martinez I et al. Peritoneal transport with 3 different peritoneal solutions [Abstract]. Nephrol Dial Transplant2003; 18(Suppl 4): S216
31. Mortier S, De Vriese AS, Van de Voorde J et al. Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration, and glucose degradation products. J Am Soc Nephrol 2002; 13: 480-489
32. Oh KH, Moon JY, Oh J et al. Baseline peritoneal solute transport rate is not associated with markers of systemic inflammation or comorbidity in incident Korean peritoneal dialysis patients. Nephrol Dial Transplant 2008; 23: 2356-2364
33. Blake PG, Flowerdew G, Blake RM et al. Serum albumin in patients on continuous ambulatory peritoneal dialysis-predictors and correlations with outcomes. J Am Soc Nephrol 1993; 3: 1501- 1507
34. Brimble KS, Walker M, Margetts PJ et al. Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 2006; 17: 2591-2598
35. Feriani M, Kirchgessner J, La Greca G et al. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int 1998; 54: 1731-1738
36. Visser CE, Brouwer-Steenbergen JJ, Betjes MG et al. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 1995; 10: 64- 69
37. Martikainen TA, Teppo AM, Gronhagen-Riska C et al. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int 2005; 25: 453-460
38. Pecoits-Filho R, Carvalho MJ, Stenvinkel P et al. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis. Perit Dial Int 2006; 26: 53-63
39. Cooker LA, Luneburg P, Holmes CJ et al. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactatebased peritoneal dialysis solutions. Perit Dial Int 2001; 21(Suppl 3): S102-S107
40. Pecoits-Filho R, Heimburger O, Barany P et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003; 41: 1212-1218